Hash oil is a resinous matrix of cannabinoids obtained from the Cannabis plant by solvent extraction, formed into a hardened or viscous mass. Hash oil can be the most potent of the main cannabis products because of its high level of psychoactive compound per its volume, which can vary depending on the plant's mix of essential oils and psychoactive compounds. Butane and supercritical carbon dioxide hash oil have become popular in recent years.
Understanding the mechanism of cannabinoid-induced analgesia has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. Cannabinoids produce analgesia through supraspinal, spinal, and peripheral modes of action, acting on both ascending and descending pain pathways. The CB1 receptor is found in both the central nervous system (CNS) and in peripheral nerve terminals. Similar to opioid receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing. CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.[43,44]
Several controlled clinical trials have been performed, and meta-analyses of these support a beneficial effect of cannabinoids (dronabinol and nabilone) on chemotherapy -induced nausea and vomiting (N/V) compared with placebo. Both dronabinol and nabilone are approved by the U.S. Food and Drug Administration for the prevention or treatment of chemotherapy-induced N/V in cancer patients but not for other symptom management.
In 1976, Canadian botanist Ernest Small and American taxonomist Arthur Cronquist published a taxonomic revision that recognizes a single species of Cannabis with two subspecies: C. sativa L. subsp. sativa, and C. sativa L. subsp. indica (Lam.) Small & Cronq. The authors hypothesized that the two subspecies diverged primarily as a result of human selection; C. sativa subsp. sativa was presumably selected for traits that enhance fiber or seed production, whereas C. sativa subsp. indica was primarily selected for drug production. Within these two subspecies, Small and Cronquist described C. sativa L. subsp. sativa var. spontanea Vav. as a wild or escaped variety of low-intoxicant Cannabis, and C. sativa subsp. indica var. kafiristanica (Vav.) Small & Cronq. as a wild or escaped variety of the high-intoxicant type. This classification was based on several factors including interfertility, chromosome uniformity, chemotype, and numerical analysis of phenotypic characters.
Out of the 17 states that have passed CBD-only laws, five— Missouri, Florida, Mississippi, Louisiana, and Texas—would also establish licensed cultivation centers to grow high-CBD strains of cannabis, which could be turned into oils and other CBD products. This would cut down on the demand for CBD oil from unregulated manufacturers abroad. Even then, though, impediments remain. In Missouri, for example, two neurologists recently refused to prescribe CBD oil for an eight- year-old boy suffering from seizures, citing concerns over federal law and the safety of non-FDA approved products.
Nabiximols (Sativex), a Cannabis extract with a 1:1 ratio of THC:CBD, is approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in advanced cancer and multiple sclerosis. Canada, New Zealand, and some countries in Europe also approve nabiximols for spasticity of multiple sclerosis, a common symptom that may include muscle stiffness, reduced mobility, and pain, and for which existing therapy is unsatisfactory.
Short-term use increases both minor and major adverse effects. Common side effects include dizziness, feeling tired, vomiting, and hallucinations. Long-term effects of cannabis are not clear. Concerns including memory and cognition problems, risk of addiction, schizophrenia in young people, and the risk of children taking it by accident.
C.S. Lewis said “badness is only spoiled goodness.” This may be an apt quote regarding public perception. It’s true that hemp’s scientific name is the same as that other Cannabis sativa, marijuana, but its constituents are different. The three cannabis plants have three different species: Sativa, used for industrial fibers, oils, food, drugs and medicine; Indica, to induce sleep; and Ruderalis, for food production. Hemp seeds contain high amounts of essential fatty acids – more than any fish and most fish oil supplements. The oil has linoleic acid, alpha-linolenic acid, and at least 20 amino acids. Altogether, hemp supplies innumerable health benefits. After decades of misunderstanding, scientists have again been tapping the amazing potential of this versatile plant.
No ongoing clinical trials of Cannabis as a treatment for cancer in humans were identified in a PubMed search. The only published trial of any cannabinoid in patients with cancer is a small pilot study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme, which demonstrated no significant clinical benefit.[19,20] In a trial (NCT02255292) conducted in Israel, oral cannabidiol (CBD) was investigated as a single salvage agent for recurrent solid tumors. The study was projected to be completed in 2015; however, no results have been published. A small exploratory phase II study (GWCA1208 Part A [NCT01812603]) was conducted in the United Kingdom that used nabiximols, a 1:1 ratio of THC:CBD in a Cannabis-based medicinal extract oromucosal spray, in conjunction with temozolomide in treating patients with recurrent glioblastoma multiforme. The study enrolled 21 patients. Final results have not been published.
Medical reviews published in 2017 and 2018 incorporating numerous clinical trials concluded that cannabidiol is an effective treatment for certain types of childhood epilepsy. An orally administered cannabidiol solution (brand name Epidiolex) was approved by the US Food and Drug Administration in June 2018 as a treatment for two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
There are ways to strain dangerous contaminants out of raw hemp paste. And most companies stand behind their quality and safety procedures. “We continuously test all our products ... to ensure our consumers get the levels of natural constituents they expect from the quality hemp stalk oil they purchase,” HempMedsPx states on its web site. “Additionally, all our products are tested for safety, to ensure there are no solvents, heavy metals, or other potentially harmful materials in our oil. Because we take these steps, we are always confident in our products, and you can be too.”